Tag: S-ICD
Novel extravascular substernal pacing as a feasible treatment option for arrhythmias
A study on substernal pacing acute clinical evaluation (SPACE) by Darius Sholevar (Our Lady of Lourdes Medical Center, Camden, USA) et al published in the...
New bio envelope designed for S-ICDs launches in USA
Aziyo Biologics has announced the launch of their CanGaroo bio envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). It is the only cardiac implantable...
S-ICD technology continues to advance rapidly
The benefits of the Subcutaneous Implantable Cardioverter Defibrillator (S-ICD, Boston Scientific) over transvenous (TV)-ICD, including lower rates of lead-related complications and lower in-hospital complication...
HRS 2017: S-ICDs successful despite a range of comorbidities, and across...
Initial real-world experience with the S-ICD (subcutaneous implantable cardioverter defibrillator) in the USA show that implant success rate is high and short-term complications acceptably...
Boston Scientific announces scheduled presentations at Heart Rhythm Society 2017
Boston Scientific has announced the schedule of key data presentations, including two late-breaking clinical trials that will be featured at the Heart Rhythm Society’s...
Modular cardiovascular device communication: A step towards artificial intelligence to treat...
The implantable cardioverter defibrillator (ICD) is a well-established therapy for the prevention of sudden cardiac death. However, it is still associated with complications over...
Acute and chronic performance of communicating leadless anti-tachycardia pacemaker and S-ICD
Martin Burke (CorVita Science Foundation, Chicago, USA) presents the preclinical acute and chronic performance of the combined implant of a leadless anti-tachycardia pacemaker and...
US FDA approves Boston Scientific Emblem MRI S-ICD system
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Emblem MRI subcutaneous implantable defibrillator (S-ICD) system, as well as magnetic...
Boston Scientific receives CE mark for MRI labelling of Emblem S-ICD...
Boston Scientific has received CE mark approval for the new Emblem MRI subcutaneous implantable defibrillator (S-ICD) system, as well as magnetic resonance (MR) conditional labelling for all previously implanted Emblem S-ICD systems.
Boston Scientific initiates study to assess Emblem S-ICD in primary prevention...
The UNTOUCHED study will compare outcomes during an 18-month follow-up period to objective performance criteria derived from the MADIT-RIT study, which evaluated shock rates in 1,500 patients implanted with transvenous ICD devices.
Entirely Subcutaneous ICD (S-ICD) poised to revolutionise treatment of Sudden Cardiac...
The publication of important new long-term data from nearly 900 patients and a rapid evolution in the technology is putting entirely the Subcutaneous Implantable...